HOME >> MEDICINE >> NEWS
Donald W. Reynolds Foundation awards UT Southwestern $12 million to continue Dallas Heart Study

DALLAS Aug. 26, 2004 A $12 million grant from the Donald W. Reynolds Foundation to UT Southwestern Medical Center at Dallas will allow researchers to continue the Dallas Heart Study, a groundbreaking investigation of cardiovascular disease involving thousands of Dallas County residents.

The Donald W. Reynolds Foundation's two-year grant to the Donald W. Reynolds Cardiovascular Clinical Research Center at UT Southwestern supplements previous foundation grants awarded to UT Southwestern totaling $30 million, bringing total Reynolds Foundation support for UT Southwestern to $42 million.

The Foundation's initial grant created the Donald W. Reynolds Cardiovascular Clinical Research Center in 1999.

The new grant will be used to continue research into the prevention and treatment of heart disease caused by atherosclerosis, or plaque buildup in the inner lining of the arteries, and by heart enlargement, which can lead to heart failure. Heart failure is the No. 1 cause of mortality in the United States and affects 5 million Americans, with more than 400,000 new cases identified each year. It also is the top cause of hospitalization for adults and accounts for more than $30 billion a year in health-care costs.

Reynolds Center researchers are using molecular and clinical research techniques to examine a large multi-ethnic group of individuals from Dallas County, to develop new biotechnology and to establish a novel training program for scientists-physicians.

Major discoveries by center-affiliated investigators since 1999 include:

  • Identification of key chemical signals that change a stem cell into a heart cell, which may lead to the ability to produce heart cells in the lab to repair a failing heart
  • Discovery of chemical signals needed for normal heart development, as well as signals involved in abnormal growth of the heart, which may lead to new drugs to prevent heart failure
  • Discovery of genes that protect
    '"/>


  • Contact: Amanda Siegfried
    Amanda.siegfried@utsouthwestern.edu
    214-648-3404
    UT Southwestern Medical Center
    26-Aug-2004


    Page: 1 2 3

    Related medicine news :

    1. Duke Universitys Cohen wins The Gerontological Society of Americas 2004 Donald P. Kent Award
    2. Wright Universitys Kapp wins The Gerontological Society of Americas 2003 Donald P. Kent Award
    3. UK researcher develops nicotinic drugs with R.J. Reynolds
    4. Can you read my mind? W.M. Keck Foundation funds innovative brain research at Carnegie Mellon
    5. Top honor for head of Epilepsy Foundation
    6. The Larry King Cardiac Foundation presents The Changing Face of Heart Disease on Feb. 2
    7. Prentiss Foundation awards $5 million to University Hospitals
    8. Endocrine Society and Hormone Foundation call for increased research
    9. Foundation to honor physicians and community health initiatives around the world
    10. NYU Child Study Center and The Bear Stearns Charitable Foundation launch outreach campaign
    11. Brain Science Institute at Columbia University established by Kavli Foundation gift

    Post Your Comments:
    (Date:3/30/2015)... March 30, 2015 Mid-America ATTC ... library of medications used in behavioral health and ... iPad and Android—is a convenient, electronic version of ... 1999. The useful resource provides up-to-date information on ... and frequency, side effects, emergency conditions, cautions, considerations ...
    (Date:3/30/2015)... Linda, CA (PRWEB) March 30, 2015 ... challenging due to the use of cellular models that ... not the entirety of the disease. , A ... human cells to precise specifications has created ... to develop environmentally and genetically driven in vitro models ...
    (Date:3/29/2015)... Calif. (PRWEB) March 30, 2015 Over ... menopause-related symptoms tied to undiagnosed autoimmune, thyroid, or hormone ... thyroid disorders, has personally treated hundreds of patients dealing ... are unaware of the treatment options for their ailments. ... offers solutions to women living with fatigue, brain fog, ...
    (Date:3/29/2015)... Telerad RxDx Multispecialty Healthcare Center, ... Accreditation on 11th January 2015. The accreditation from ... Providers) comes as a true recognition of the ... RxDx., With Telerad RxDx being the first healthcare ... marks a major achievement and a significant step ...
    (Date:3/29/2015)... March 29, 2015 At this ... platform provides basic health information around medical conditions ... discuss these challenges as well as helping them ... addresses six medical conditions using evidenced based information ... engage in conversations around them., ...
    Breaking Medicine News(10 mins):Health News:Popular Publication on Behavioral Health Medications Now An App 2Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 2Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 3Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 4Health News:How to Turn Mid-life into the Good Life 2Health News:NABH Accreditation for Telerad RxDx – Whitefield. 2Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 2Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 3
    (Date:3/30/2015)... , March 30, 2015  BioDelivery Sciences International, ... primary efficacy endpoint in the Phase 3 clinical ... for the treatment of painful diabetic neuropathy did ... showed statistically significant improvement over placebo.  In addition, ... observed.  The results of this trial provide data ...
    (Date:3/29/2015)... 2015  Three-month paliperidone palmitate, an investigational atypical ... placebo in patients with schizophrenia, according to a ... in the Journal of the American ... Results of the study served as the basis ... for three-month paliperidone palmitate injection to treat schizophrenia ...
    (Date:3/27/2015)... - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: ... issuance of an aggregate of 30,000 stock options to ... of 120,500 stock options to employees and consultants of ... years and will be exercisable for a period of ... stock option. About Covalon Covalon Technologies ...
    Breaking Medicine Technology:BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 2BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 3BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 4BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12Covalon Announces Issuance of Stock Options 2
    Cached News: